Featured Research

from universities, journals, and other organizations

Assuring The Supply Of Vaccines

Date:
June 22, 2005
Source:
Elsevier Health Sciences
Summary:
The recent shortage of flu vaccine, which eventually became a surplus, points to problems with vaccine financing and production. Various solutions to these problems have been proposed, but there has been no consensus on the path to take. In an article published in the July issue of the American Journal of Preventive Medicine, a summary of the findings of the Vaccine Financing Workgroup of the National Vaccine Advisory Committee (NVAC) suggests several steps to improve the present situation.

The recent shortage of flu vaccine, which eventually became a surplus, points to problems with vaccine financing and production. Various solutions to these problems have been proposed, but there has been no consensus on the path to take. In an article published in the July issue of the American Journal of Preventive Medicine, a summary of the findings of the Vaccine Financing Workgroup of the National Vaccine Advisory Committee (NVAC) suggests several steps to improve the present situation. These recommendations differ from those of a recent Institute of Medicine (IOM) report.

During 2003-2004, the NVAC working group conducted a series of discussions and meetings leading to a proposal for substantial, but incremental, changes to the current system that the group feels would go a long way toward stabilizing the financing of immunizations in the United States. In contrast to the IOM recommendation to replace the current immunization financing system with an insurance mandate and system of subsidies and vouchers, the NVAC would like to see "expanded and stable funding for the existing immunization grant program, expansion of the Vaccines for Children program, regulatory harmonization, promotion of 'first dollar' insurance coverage for immunizations, and the assurance of adequate reimbursement for the administration of vaccines."

When the IOM recommended, among other things, that insurers be required to cover immunizations, that vaccine prices be set in advance of their development, and that vaccine coverage decisions include societal benefits and costs, including consideration of the impact of the price of a vaccine on recommendations for its use, there were widespread and varied responses. Editorials in the Wall Street Journal and the New York Times helped raise awareness of the complexities surrounding the vaccine industry. A briefing was held at the American Enterprise Institute at which reservations were expressed by many stakeholders about the Committee's recommendations. Questions and comments were raised by The Winter Immunization Forum of the National Partnership for Immunization and in an editorial comment in the journal Pediatrics by the past president of the American Academy of Pediatrics.

The National Vaccine Advisory Committee (NVAC) makes several recommendations to stabilize financing of immunizations in the Untied States, including: expanded and stable funding through Section 317 of the Public Health Service Act for immunization program infrastructure and operations, as well as for vaccine purchase; expanded funding through Section 317 to support adolescent and adult immunization programs; expansion of the Vaccines for Children Program to include underinsured children in all public health clinics; promotion of "first-dollar" insurance coverage for immunization; and assurance of adequate reimbursement for administration of vaccines.

The article is titled "Financing Vaccines in the 21st Century: Recommendations from the National Vaccine Advisory Committee" by Alan R. Hinman, MD, MPH, for the National Vaccine Advisory Committee and appears in the July issue of the American Journal of Preventive Medicine (Volume 29, Number 1) published by Elsevier.


Story Source:

The above story is based on materials provided by Elsevier Health Sciences. Note: Materials may be edited for content and length.


Cite This Page:

Elsevier Health Sciences. "Assuring The Supply Of Vaccines." ScienceDaily. ScienceDaily, 22 June 2005. <www.sciencedaily.com/releases/2005/06/050621073901.htm>.
Elsevier Health Sciences. (2005, June 22). Assuring The Supply Of Vaccines. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2005/06/050621073901.htm
Elsevier Health Sciences. "Assuring The Supply Of Vaccines." ScienceDaily. www.sciencedaily.com/releases/2005/06/050621073901.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins